Drug Approval | April 14, 2025
Aurolife Pharma gets 11 observations from USFDA for Raleigh plant
The company does not expect this development to have any material impact on the current business operations
The company does not expect this development to have any material impact on the current business operations
The supply of these goods is set to commence within the first quarter of FY26
The Atlan A100 system delivers advanced ventilation technology for adults, pediatric patients, and neonates, revolutionizing care with seamless workflows across hospital departments
The approval was granted more than two months ahead of the Prescription Drug User Fee Act goal date
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
The company has entered into above Memo to settle, compromise and finally and forever resolve all disputes
Strengthening capabilities in Peptide Therapeutics and CDMO services
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs’ proprietary Oral Thin Film technology platform, ThinOral
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Subscribe To Our Newsletter & Stay Updated
